A Bayesian Response-Adaptive Randomization Design for Clinical Trials with Survival Endpoints

@inproceedings{2016ABR,
  title={A Bayesian Response-Adaptive Randomization Design for Clinical Trials with Survival Endpoints},
  author={},
  year={2016}
}
  • Published 2016
Accordingly to FDA draft guidance (2010), adaptive randomization (e.g. responseadaptive (RA) randomization) has become popular in clinical research because of its flexibility and efficiency, which also have the advantage of assigning fewer patients to inferior treatment arms. The RA design based on binary outcome is commonly used in clinical trial where “success” is defined as the desired (or undesired) event occurring within (or beyond) a clinical relevant time. As patients entering into trial… CONTINUE READING